Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on developing novel treatments for debilitating liver diseases.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Mirum Pharmaceuticals' stock with a target price of $58.5, indicating potential growth.
Financial Health
Mirum Pharmaceuticals is performing well with strong revenue and cash flow, indicating healthy operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring MIRM
Pharma M&A Targets (Metabolic Disease Biotechs)
Novo Nordisk's $5.2 billion acquisition of Akero Therapeutics highlights a strategic push into the MASH treatment market. This deal could trigger a wave of similar acquisitions, boosting the value of other biotech firms with promising drugs for metabolic diseases.
Published: October 10, 2025
Explore BasketMASH Stocks: Could Roche's Deal Spark More M&A?
Roche's $3.5 billion acquisition of 89bio for its liver disease drug highlights the growing MASH treatment market. This deal creates a potential tailwind for other biopharmaceutical companies developing therapies for liver and metabolic conditions.
Published: September 21, 2025
Explore BasketMASH Drug Developers Could Attract M&A in 2025
Roche's $3.5 billion deal to acquire 89bio for its late-stage liver disease drug highlights the immense commercial potential seen in the MASH treatment landscape. This move could trigger a wave of investment and further acquisitions, benefiting other biotech firms with promising therapies for metabolic disorders.
Published: September 19, 2025
Explore BasketMASH Biotech Stocks: What's Next After Roche Deal
Roche's acquisition of 89bio for its late-stage liver disease drug highlights a major strategic investment in the MASH treatment space. This move could increase the valuation of other biotech companies developing therapies for metabolic disorders as they become attractive M&A targets.
Published: September 18, 2025
Explore BasketWhich Pharma Stocks Could Follow Wegovy's Success?
Following the FDA's approval of Novo Nordisk's Wegovy for a common liver disease, this theme focuses on pharmaceutical companies developing treatments for metabolic disorders. This development opens a new market for weight-loss drugs and signals opportunity for firms with therapies targeting related conditions.
Published: August 21, 2025
Explore BasketGLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Published: August 19, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Rare‑disease focus
Concentrating on small, high‑need patient groups can mean regulatory incentives and premium pricing, though market size may limit revenue upside.
Regulatory catalysts
Milestones such as approvals or label expansions can move the stock; clinical setbacks can have the opposite effect, so outcomes are binary and impactful.
Commercial execution
Scaling sales, securing reimbursement and manufacturing reliably are essential to translate approvals into sustainable revenue; execution risks remain.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
